EFDA Recognized Standards for Medical Device Conformity in Ethiopia

1. Key takeaways

On July 17, 2026, Ethiopia published the Recognized Standards by EFDA in its publications library as the technical basis for medical device conformity evaluation. In the non-IVD dossier, standards are listed as an independent item of Chapter 3 (EFDA/GDL/097 Section 3.3), alongside risk management and the Essential Principles checklist. Adopting recognized standards and maintaining a version ledger is the necessary step for translating technical evidence into regulatory language.

The standards item answers a specific question in the evidence chain: the Essential Principles state what must be conformed to, the non-clinical studies show what was tested, and the standards state by which methods the testing was performed. When each test report in the dossier names a recognized standard and version, the reviewer can verify the method behind every conclusion without issuing queries. When the dossier instead references ad hoc methods or outdated versions, each report becomes an open question.

The timing also matters. The recognized standards list appeared in July 2026, the Version 002 non-IVD dossier guideline took effect on June 30, 2026, and the vigilance and FSCA guideline was published in July 2026. Three instruments released in the same window show that EFDA is advancing guidelines, standards and document control in step, and manufacturers should expect further coordinated updates rather than isolated changes.

2. Legal basis

3. Expert insights

Insight 1: the recognized standards list appeared almost in step with the dossier revision, as part of systematic capacity building. The Recognized Standards list came online in July 2026, the Version 002 non-IVD dossier took effect on June 30, 2026, and the vigilance and FSCA guideline came online in July 2026. The three actions concentrated in the same window show that EFDA is advancing guidelines, standards and document control in a synchronized way. For manufacturers, this means the recognized list should be consulted at the start of every dossier project and re-checked at submission, because additions during this build-out period are likely.

Insight 2: the standards item (Section 3.3) explains by what method conformity is demonstrated. The Essential Principles answer what must be conformed to, the non-clinical studies answer what was tested, and the standards answer by what method it was tested. With any one of the three missing, the evidence chain is incomplete. A dossier that reports test results without naming the standard under which the tests were performed forces the reviewer to reconstruct the methodology, and that reconstruction rarely favours the manufacturer. Naming the standard, edition and clause-level deviations for each report closes this gap.

Insight 3: standard version management is a substantive compliance requirement. When adopting standards, the dossier must state the standard number and version and indicate whether there are deviations. After a standard is revised, whether test reports under the old version are still accepted must be confirmed case by case; this is a high-frequency query point at renewal and change filings. A version ledger that records, for each standard used, the edition, the date of testing and the report reference turns a potentially disruptive transition into a managed update with an evidence trail.

Insight 4: the depth of evidence scales with class and technological novelty, and the choice of standards scales with it. Section 7.3 establishes that the range of evidence increases with the device class, complexity and the extent of adoption of new technologies. For products embodying new technologies where no directly applicable recognized standard exists, the reasonableness of the chosen alternative method must be explained. This justification should describe why the substitute method addresses the same safety or performance question as a recognized standard would, and what validation supports the method itself.

Insight 5: recognized standards are not equivalent to a waiver of national requirements. The recognized standards list is a menu of usable methods and does not mean the authority gives up reviewing specific national requirements (for example, requirements applicable to radiation-emitting devices). Section 7.3 makes explicit that the technical documentation must also conform to other national regulatory requirements. Manufacturers should therefore run two checks in parallel: conformity to the recognized standards for methods, and conformity to the national requirements that sit outside the standards framework.

4. Practical recommendations

1. Download the current Recognized Standards list and establish a ledger: record standard numbers and versions.
2. List all adopted standards and versions in Section 3.3 of the dossier: and state deviations.
3. Select standards according to the non-clinical study items: build a mapping table item by item.
4. When a standard is revised, assess the acceptance of existing reports: supplement testing where necessary.
5. Where no directly applicable standard exists, justify the alternative method.
6. Check national-specific requirements in parallel: such as those for radiation-emitting devices.

5. Verification checklist

• □ The current version of the EFDA Recognized Standards list has been obtained
• □ The standards and versions adopted have been stated in Section 3.3 of the dossier
• □ A mapping table between standards and non-clinical study items has been established
• □ Any deviations from the standards have been stated (if any)
• □ The impact of standard revisions on existing test reports has been assessed
• □ National-specific requirements (such as radiation-emitting devices) have been checked

Regulatory information verified as of October 29, 2026. The launch date of the recognized standards and the dossier items listed in this article are based on the current information in the EFDA publications library and EFDA/GDL/097 Section 3.3; when the list is updated, they must be re-checked.

• Ethiopia local resource: GRZAN can assist manufacturers from the Chinese mainland and overseas with marketing authorization (MA), Certificate of Competency (CoC) and import licence applications to the Ethiopian Food and Drug Authority (EFDA), including local agent planning and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization application and re-registration, applicability determination for the low-risk notification procedure, Essential Principles conformity justification, labelling and IFU localization (English), and vigilance reporting and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.